Literature DB >> 24321897

Usefulness of pharmacologic conversion of atrial fibrillation during dofetilide loading without the need for electrical cardioversion to predict durable response to therapy.

Rohit Malhotra1, Kenneth C Bilchick2, John P DiMarco2.   

Abstract

Conversion of persistent atrial fibrillation (AF) to sinus rhythm is frequently seen during the 3-day in-hospital loading period required during dofetilide initiation, but it is not known whether pharmacologic conversion (PC) without the need for electrical cardioversion (EC) is a predictor of long-term maintenance of sinus rhythm during continued therapy with dofetilide. We sought to test the hypothesis that PC predicts durable maintenance of sinus rhythm and determine additional predictors of long-term maintenance of sinus rhythm on dofetilide. We retrospectively reviewed all elective inpatient admissions for dofetilide loading from 2003 to 2011 at the University of Virginia. A multivariate Cox proportional hazards model was used to assess predictors of maintenance of sinus rhythm after in-hospital dofetilide loading. In all, 101 patients with a current duration of AF lasting for a median of 1.86 months (interquartile range 0.47 to 6.03) were included in the analysis. Forty-seven patients were in the PC group, whereas 54 patients were in the EC group. Patients in the PC group remained longer in sinus rhythm compared with the patients in the EC group (log-rank p = 0.032). The seventy-fifth percentile for the current episode duration in the PC group was 5.77 months, indicating that even long-standing persistent AF frequently converted pharmacologically. Hypertension and a longer duration of the current AF episode were also predictors of recurrence in the multivariate model. In conclusion, PC during in-hospital dofetilide loading is an important predictor of durable response even in long-standing persistent patients, which has important public health implications for choice of therapy.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24321897      PMCID: PMC3932309          DOI: 10.1016/j.amjcard.2013.10.031

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  18 in total

1.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart
Journal:  J Am Soc Echocardiogr       Date:  2005-12       Impact factor: 5.251

Review 2.  Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation.

Authors:  Rachel R Huxley; Kristian B Filion; Suma Konety; Alvaro Alonso
Journal:  Am J Cardiol       Date:  2011-04-27       Impact factor: 2.778

3.  Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.

Authors:  D Roy; M Talajic; P Dorian; S Connolly; M J Eisenberg; M Green; T Kus; J Lambert; M Dubuc; P Gagné; S Nattel; B Thibault
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

4.  Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study.

Authors:  Lars Frost; Lone Juul Hune; Peter Vestergaard
Journal:  Am J Med       Date:  2005-05       Impact factor: 4.965

Review 5.  Dofetilide: a new class III antiarrhythmic agent.

Authors:  Henri Roukoz; Walid Saliba
Journal:  Expert Rev Cardiovasc Ther       Date:  2007-01

6.  Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.

Authors:  S Singh; R G Zoble; L Yellen; M A Brodsky; G K Feld; M Berk; C B Billing
Journal:  Circulation       Date:  2000-11-07       Impact factor: 29.690

7.  Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.

Authors:  C Torp-Pedersen; M Møller; P E Bloch-Thomsen; L Køber; E Sandøe; K Egstrup; E Agner; J Carlsen; J Videbaek; B Marchant; A J Camm
Journal:  N Engl J Med       Date:  1999-09-16       Impact factor: 91.245

8.  Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter.

Authors:  Javier E Banchs; Deborah L Wolbrette; Soraya M Samii; Erica D Penny-Peterson; Parag P Patel; Sallie K Young; Mario D Gonzalez; Gerald V Naccarelli
Journal:  J Interv Card Electrophysiol       Date:  2008-08-08       Impact factor: 1.900

Review 9.  New risk factors for atrial fibrillation: causes of 'not-so-lone atrial fibrillation'.

Authors:  Bas A Schoonderwoerd; Marcelle D Smit; Lucas Pen; Isabelle C Van Gelder
Journal:  Europace       Date:  2008-05-13       Impact factor: 5.214

Review 10.  Atrial fibrillation and congestive heart failure: risk factors, mechanisms, and treatment.

Authors:  E Kevin Heist; Jeremy N Ruskin
Journal:  Prog Cardiovasc Dis       Date:  2006 Jan-Feb       Impact factor: 8.194

View more
  3 in total

1.  Acute conversion of persistent atrial fibrillation during dofetilide loading does not predict long-term atrial fibrillation-free survival.

Authors:  Shaan Khurshid; Simon Akerman; Jonathan P Man; Gregory Supple; Sanjay Dixit; Andrew E Epstein; Francis E Marchlinski; David S Frankel
Journal:  J Interv Card Electrophysiol       Date:  2015-01-27       Impact factor: 1.900

Review 2.  Who Needs Pharmacologic Therapy?

Authors:  Christopher P Porterfield; Rohit Malhotra
Journal:  J Atr Fibrillation       Date:  2014-06-30

3.  Individual Contributions of Cardiac Ion Channels on Atrial Repolarization and Reentrant Waves: A Multiscale In-Silico Study.

Authors:  Henry Sutanto
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.